Tweets
ACR2022 Topic Panels https://t.co/5gMfFS8maR
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
@rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs from this study and yet still two people in the turmeric arm got LFT derangement (vs zero in placebo). Sadly I don't think the turmeric salespeople are watching the LFTs.
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Abstr #2191 studies impact of maternal SLE on outcomes of children
Maternal SLE assoc w/ ↑ odds of
- SLE of children (HR 98.48, 95%CI:63.39-152.98)
- other AutoImm dx (HR 1.26, 1.02-1.57) (Hashimoto, JRA, IBD)
- Neurodev dx (1.35, 95%CI:1.15-1.57) (ADHD)
@RheumNow #ACR22
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
How to adjust for GC correction when dose >/= 7.5mg/d using FRAX?
Calculate FRAX then
🦴For MOF risk multiply by 1.15
🦴HF risk multiply by 1.2
= adjusted risk (%)
(Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011)
#ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h
sheila @RHEUMarampa ( View Tweet )
3 years 8 months ago
What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for NIH in >2800 Pts from 1984-2020 in well characterized Pts. Abst#2025 #ACR22 @RheumNow I was surprised as I thought there would be worsening but if prevalent Pts already fibrotic?
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smoking, disease activity @RheumNow #ACR22 Abstr#2250 https://t.co/Hw2oBawKsd https://t.co/DqCQIPpEyg
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose
- anti-SARS-CoV2 IgG levels ↑ after day 1
- Saliva IgG also ↑ up to day 14
- one reported COVID+ w mild symptoms
@RheumNow #ACR22 https://t.co/um2JFNMhpj
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patients May activate the complement cascade and contribute to brain white matter changes. @RheumNow #ACR22 Abstr#2269 https://t.co/JrjNvQRDim https://t.co/c4yXHLOmBJ
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Planned for 150 Pts but only 51 enrolled but p=0.9. A trial recruited during #COVID so difficult to enroll Abst#530 @RheumNow #ACR22 https://t.co/CBYEJ2YCVM
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a difference? @RheumNow #ACR22
https://t.co/2oJ1RAeciN https://t.co/c9s6QRSOR4
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow #ACR22 Abstr#2251 #ACRbest https://t.co/R5rQ3KcHnq https://t.co/8Nq0t4zqQK
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
